Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Compass Pathways Announces Pricing of Underwritten Offering
-
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
-
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
-
Specificity Eyes 2025 for Serious Growth
-
Tilray Brands Reports Q2 2025 Financial Results
-
Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O’Neill, Ph.D.
-
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
-
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
-
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
-
MD Logic Health® Introduces Cool: A Breakthrough In Women's Hormonal Health!
-
Nickel Sulphate Futures Now Live for Trading on Abaxx Exchange
-
New Book Unveils a Neuroscience-Based Framework to Break Free from Divorce Indecision in Just 30 Days
-
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
-
Bio-Path Holdings Provides 2025 Clinical and Operational Update
-
Lantronix Names Brent Stringham as CFO
-
Plymouth Industrial REIT Provides Activity Update for Fourth Quarter 2024
-
Aircastle Announces Third Quarter 2024 Results
-
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
-
Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
-
Empowering the Next Generation: Aurora Announces German Internship Program
-
Neogen Announces Preliminary¹ Second-Quarter 2025 Results
-
U.S. Energy Corp. Announces Recent AcquisitionTargeting Industrial Gas Production
-
Gencor Announces Receipt of NYSE Regulation Notice Regarding Late Filing of the Annual Report on Form 10-K for the Year Ended September 30, 2024
-
Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
-
AKTIS ONCOLOGY TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
-
Branford Castle Acquires Eastern Dental Management, a Leading Dental Services Organization, from Staple Street Capital
-
Walgreens Boots Alliance Reports Fiscal 2025 First Quarter Results
-
Cipia unveils ADAS capabilities for Cipia-FS10, redefining its fleet safety offering with a 360° Road and Driver Monitoring Solution
-
The Tel-Aviv Stock Exchange Reports Buyback of the Company's shares from Manikay Fund
-
Introducing Pairzon's Next Generation Media Mix Modeling (MMM) Tool
-
CI Financial Announces Filing and Mailing of Circular for Special Meeting to Approve Plan of Arrangement with Mubadala Capital
-
The New York Stem Cell Foundation Research Institute Enters Agreement to Accelerate Precision Drug Discovery for Neurodegenerative Disease
-
Top Food Trends of 2025 That Will Have You Choosing Beef
-
Chemtrade Logistics Income Fund Issues 2025 Guidance and Raises Monthly Distribution
-
The “Hottest” Bagel in New York is Opening Its First Boston Location
-
Fintech nsave launches investment platform, offering people from distressed economies protection from inflation with compliant and safe investments abroad
-
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
-
First of Four Next Health Nashville Locations Opening in The Gulch January 2025
-
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
-
AtlasClear Holdings, Inc. 2025 Stockholder Letter
-
Chemtrade Logistics Income Fund Announces Appointment of Trustee
-
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
-
D-Wave Announces Fiscal Year 2024 Bookings Will Exceed $23 Million, Up Approximately 120% Over Fiscal Year 2023
-
ez1099 2024 Edition Tax Preparation Software for 2025 Tax Season Is Available for Electronic Filing
-
Walden Biosciences Highlights 2024 Accomplishments and 2025 Priorities
-
RMHC Bay Area Welcomes Six New Board Members to Strengthen Mission and Community Engagement
-
Bunge Schedules Fourth Quarter 2024 Earnings Release and Conference Call
-
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
-
Green Thumb Industries Announces First-Of-Its-Kind Partnership with Iconic Chicago Music Venue, The Salt Shed, Introducing Retail Store RISE at Salt Shed and RYTHM Brand Activations

